12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Plecanatide: Completed Phase IIb/III enrollment

Synergy completed enrollment of about 880 patients in a double-blind, placebo-controlled, U.S. Phase IIb/III trial (SP304-20210) evaluating 0.3, 1 or 3 mg oral plecanatide once daily for 12 weeks. In July, Synergy said it will...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >